Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections
Open Access
- 4 September 2025
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 14 (9) , 894
Abstract
Infections caused by MBL-producing Gram-negative bacterial pathogens have disseminated worldwide and are associated with considerable morbidity and mortality. We evaluated the published clinical evidence on the use of various antibiotics for the treatment of patients with such infections. The available data suggest the consideration of the new antibiotics cefiderocol and aztreonam-avibactam for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens. However, their considerable cost and limited availability hinder their use. Also, the combination of ceftazidime-avibactam and aztreonam has been occasionally used, especially when there was an unavailability of aztreonam-avibactam. Additionally, old antibiotics such as colistin and fosfomycin, especially in combination antimicrobial therapy, may be considered for the treatment of patients with such infections. The relevant clinical data on the use of tigecycline and aminoglycosides for infections caused by MBL-producing pathogens are limited. Thus, the evaluation of the published evidence suggests the best treatment options for the treatment of patients with such infections at present. Also, the limited available data highlight the need for dissemination of the already acquired clinical experience and the conduct of new studies examining currently available antibiotics, as well as investigational antimicrobial agents for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens.Keywords
This publication has 41 references indexed in Scilit:
- Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trialsExpert Opinion on Investigational Drugs, 2025
- Past, present, and future perspectives on aztreonam and avibactamExpert Review of Anti-infective Therapy, 2025
- Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysisClinical Microbiology and Infection, 2023
- Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitisInternational Journal of Infectious Diseases, 2021
- Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonamScientific Reports, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two casesInternational Journal of Antimicrobial Agents, 2020
- Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agentsInternational Journal of Antimicrobial Agents, 2010
- Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteriaEuropean Journal of Clinical Pharmacology, 2010
- Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studiesInternational Journal of Antimicrobial Agents, 2009